Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)

References

• Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol. 2014;101-102:161–167. doi: 10.1016/j.jri.2013.07.005
   PubMed Web of Science ®Google Scholar
• Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology. 1994;50(6):387–394. doi: 10.1002/tera.1420500604
   PubMedGoogle Scholar
• Minsker DH, MacDonald JS, Robertson RT, et al. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology. 1983;28(3):449–456. doi: 10.1002/tera.1420280316
   PubMedGoogle Scholar
• Chang JC, Chen YJ, Chen IC, et al. Perinatal outcomes after statin exposure during pregnancy. JAMA Netw Open. 2021;4(12):e2141321. doi: 10.1001/jamanetworkopen.2021.41321
   PubMed Web of Science ®Google Scholar
• Kusters DM, Hassani Lahsinoui H, van de Post JA, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2012;10(3):363–378. doi: 10.1586/erc.11.196
   PubMedGoogle Scholar
• Thobani A, Hassen L, Mehta LS, et al. Management of hypercholesterolemia in pregnant women with atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2021;23(10):58. doi: 10.1007/s11883-021-00957-w
   PubMed Web of Science ®Google Scholar
• Christensen JJ, Bogsrud MP, Holven KB, et al. Use of statins and other lipid-modifying agents across pregnancy: a nationwide drug utilization study in Norway in 2005-2018. Atherosclerosis. 2023;368:25–34. doi: 10.1016/j.atherosclerosis.2022.11.022
   PubMed Web of Science ®Google Scholar
• Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(5):478–485. doi: 10.1016/j.contraception.2011.07.013
   PubMed Web of Science ®Google Scholar
• Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG: Int J Obstet Gy. 2020;127(4):478–488. doi: 10.1111/1471-0528.16013
   PubMed Web of Science ®Google Scholar
• Wei J, Liao JK, Bairey Merz CN. Challenging statin pleiotropy: preeclampsia. Circulation. 2021;144(9):680–683. doi: 10.1161/CIRCULATIONAHA.121.056140
   PubMed Web of Science ®Google Scholar
• Toleikyte I, Retterstøl K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124(15):1606–1614. doi: 10.1161/CIRCULATIONAHA.110.990929
   PubMed Web of Science ®Google Scholar
• Nangrahary M, Graham DF, Pang J, et al. Familial hypercholesterolaemia in pregnancy: Australian case series and review. Aust N Z J Obstet Gynaecol. 2023;63(3):402–408. doi: 10.1111/ajo.13657
   PubMed Web of Science ®Google Scholar
• Lee MS, Hekimian A, Doctorian T, et al. Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. Int J Cardiol. 2018;269:111–113. doi: 10.1016/j.ijcard.2018.07.002
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Makvandi S, Banach M, et al. Fetal toxicity associated with statins: a systematic review and meta-analysis. Atherosclerosis. 2021;327:59–67. doi: 10.1016/j.atherosclerosis.2021.05.006
   PubMed Web of Science ®Google Scholar
• Karalis DG, Hill AN, Clifton S, et al. The risks of statin use in pregnancy: a systematic review. J Clin Lipidol. 2016;10(5):1081–1090. doi: 10.1016/j.jacl.2016.07.002
   PubMed Web of Science ®Google Scholar
• Meijerink L, Wever KE, Terstappen F, et al. Statins in pre-eclampsia or fetal growth restriction: a systematic review and meta-analysis on maternal blood pressure and fetal growth across species. BJOG. 2023;130(6):577–585. doi: 10.1111/1471-0528.17393
   PubMedGoogle Scholar
• Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):.e720.1–.e720.17. doi: 10.1016/j.ajog.2015.12.038
   Web of Science ®Google Scholar
• Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation. 2021;144(9):670–679. doi: 10.1161/CIRCULATIONAHA.121.053963
   PubMed Web of Science ®Google Scholar
• Costantine MM, West H, Wisner KL, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021;225(6):.e666.1–.e666.15. doi: 10.1016/j.ajog.2021.05.018
   Web of Science ®Google Scholar
• Pham A, Polic A, Nguyen L, et al. Statins in pregnancy: can we justify early treatment of reproductive aged women? Curr Atheroscler Rep. 2022;24(8):663–670. doi: 10.1007/s11883-022-01039-1
   PubMed Web of Science ®Google Scholar
• Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with Entecavir and Adefovir: New Insights from a real-world analysis of cases reported to FDA adverse Event reporting System. Front Pharmacol. 2021;12:772768. doi: 10.3389/fphar.2021.772768
   PubMed Web of Science ®Google Scholar
• Wu T, Zhang Y, Shi Y, et al. Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse Event reporting System database. Clin Drug Investig. 2022;42(11):965–975. doi: 10.1007/s40261-022-01202-1
   PubMed Web of Science ®Google Scholar
• Chen C, Chen T, Liang J, et al. Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS. Front Pharmacol. 2021;12:616505. doi: 10.3389/fphar.2021.616505
   PubMed Web of Science ®Google Scholar
• Lewek J, Banach M. Dyslipidemia management in pregnancy: why is it not covered in the guidelines? Curr Atheroscler Rep. 2022;24(7):547–556. doi: 10.1007/s11883-022-01030-w
   PubMed Web of Science ®Google Scholar
• Setyawan J, Azimi N, Strand V, et al. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019. Drug Saf. 2021;44(8):889–897. doi: 10.1007/s40264-021-01082-y
   PubMed Web of Science ®Google Scholar
• Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30(7):623–625. doi: 10.2165/00002018-200730070-00011
   PubMed Web of Science ®Google Scholar
• Grant JK, Snow S, Kelsey M, et al. Lipid-lowering therapy in women of childbearing age: a review and stepwise clinical approach. Curr Cardiol Rep. 2022;24(10):1373–1385. doi: 10.1007/s11886-022-01751-z
   PubMed Web of Science ®Google Scholar
• Mother To Baby | Fact Sheets [Internet]. Evolocumab (Repatha®) 2021 Feb 1. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994 [cited 2023 Mar 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582695/
   Google Scholar
• Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350(mar17 10):h1035. doi: 10.1136/bmj.h1035
   PubMedGoogle Scholar
• US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. [cited 2023 Mar 16]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
   Google Scholar
• Hirsch A, Ternovsky N, Zwas DR, et al. The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1003060. doi: 10.3389/fphar.2022.1003060
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. 2021;336:1–11. doi: 10.1016/j.atherosclerosis.2021.09.010
   PubMed Web of Science ®Google Scholar
• Jyoti S, Tandon S. Genetic basis for developmental toxicity due to statin intake using embryonic stem cell differentiation model. Hum Exp Toxicol. 2015;34(10):965–984. doi: 10.1177/0960327114564795
   PubMed Web of Science ®Google Scholar
• Ghidini A, Sicherer S, Willner J. Congenital abnormalities (VATER) in baby born to mother using lovastatin. Lancet. 1992;339(8806):1416–1417. doi: 10.1016/0140-6736(92)91237-3
   PubMed Web of Science ®Google Scholar
• Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. 2022;226(2s):S1171–s1181. doi: 10.1016/j.ajog.2020.08.040
   PubMedGoogle Scholar
• Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56(1):166–171. doi: 10.1161/HYPERTENSIONAHA.110.150078
   PubMed Web of Science ®Google Scholar
• Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120(4):463–471. doi: 10.1111/1471-0528.12066
   PubMed Web of Science ®Google Scholar
• Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–1150. doi: 10.1016/j.cjca.2021.03.016
   PubMed Web of Science ®Google Scholar
• Sunman H, Canpolat U, Sahiner L, et al. Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. Ann Pharmacother. 2012;46(2):e5. doi: 10.1345/aph.1Q626
   PubMedGoogle Scholar
• Whitten AE, Lorenz RP, Smith JM. Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. Obstet Gynecol. 2011;117(2 Pt 2):517–519. doi: 10.1097/AOG.0b013e31820755b5
   PubMed Web of Science ®Google Scholar
• Vuignier Y, Beaud F, Kosinski C, et al. Exposure to alirocumab during the first trimester of pregnancy: A case report. Birth Defects Res. 2021;113(15):1156–1160. doi: 10.1002/bdr2.1930
   PubMedGoogle Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241. doi: 10.1093/eurheartj/ehy340
   PubMed Web of Science ®Google Scholar